Tazicef Dosage

Generic name: ceftazidime
Dosage form: injection, powder, for solution

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Dosage: The usual adult dosage is 1 gram administered intravenously or intramuscularly every 8 to 12 hours. The dosage and route should be determined by the susceptibility of the causative organisms, the severity of infection, and the condition and renal function of the patient.

The guidelines for dosage of Tazicef (ceftazidime for injection, USP) are listed in Table 5. The following dosage schedule is recommended. 

Table 5. Recommended Dosage Schedule
*
Although clinical improvement has been shown, bacteriologic cures cannot be expected in patients with chronic respiratory disease and cystic fibrosis.
The higher dose should be reserved for immunocompromised pediatric patients or pediatric patients with cystic fibrosis or meningitis.

Dose

Frequency

Adults

Usual recommended dosage

1 gram IV or IM

q8-12hr

Uncomplicated urinary tract infections

250 mg IV or IM

q12hr

Bone and joint infections

2 grams IV

q12hr

Complicated urinary tract infections

500 mg IV or IM

q8-12hr

Uncomplicated pneumonia; mild skin and

skin-structure infections

500 mg to 1 gram

IV or IM

q8hr
  

Serious gynecologic and
intra-abdominal infections

2 grams IV
  

q8hr
                               

Meningitis

2 grams IV

q8hr

Very severe life-threatening infections,
especially in immunocompromised patients

2 grams IV
                            

q8hr
  

Lung infections caused by

Pseudomonas spp. in patients with cystic

fibrosis with normal renal function*

30 to 50 mg/kg IV

to a maximum

of 6 grams per day

q8hr
  
  

Neonates (0 – 4 weeks)

30 mg/kg IV

q12hr

Infants and children

(1 month – 12 years)
   

30 to 50 mg/kg IV

to a maximum

of 6 grams per day

q8hr
   
  

Impaired Hepatic Function

No adjustment in dosage is required for patients with hepatic dysfunction.

Impaired Renal Function

Ceftazidime is excreted by the kidneys, almost exclusively by glomerular filtration. Therefore, in patients with impaired renal function (glomerular filtration rate [GFR] <50 mL/min), it is recommended that the dosage of ceftazidime be reduced to compensate for its slower excretion. In patients with suspected renal insufficiency, an initial loading dose of 1 gram of ceftazidime may be given. An estimate of GFR should be made to determine the appropriate maintenance dosage. The recommended dosage is presented in Table 6.

Table 6. Recommended Maintenance Dosages of Tazicef (ceftazidime for injection, USP) in Renal Insufficiency

NOTE: IF THE DOSE RECOMMENDED IN TABLE 5 ABOVE IS LOWER THAN THAT RECOMMENDED FOR PATIENTS WITH RENAL INSUFFICIENCY AS OUTLINED IN TABLE 6, THE LOWER DOSE SHOULD BE USED.

Creatinine Clearance

(mL/min)

Recommended Unit Dose of

Tazicef

Frequency of Dosing

50 to 31

1 gram

q12hr

30 to 16

1 gram

q24hr

15 to 6

500 mg

q24hr

<5

500 mg

q48hr

When only serum creatinine is available, the following formula (Cockcroft’s equation)4 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function:

Males: Creatinine clearance (mL/min) =                               [Weight (kg) x (140 - age)]                  
                                                                                            [ 72 x serum creatinine (mg/dL)]

Females: 0.85 x male value

In patients with severe infections who would normally receive 6 grams of Tazicef daily were it not for renal insufficiency, the unit dose given in the table above may be increased by 50% or the dosing frequency may be increased appropriately. Further dosing should be determined by therapeutic monitoring, severity of the infection, and susceptibility of the causative organism.

In pediatric patients as for adults, the creatinine clearance should be adjusted for body surface area or lean body mass, and the dosing frequency should be reduced in cases of renal insufficiency.

In patients undergoing hemodialysis, a loading dose of 1 gram is recommended, followed by 1 gram after each hemodialysis period.

Tazicef (ceftazidime for injection, USP) can also be used in patients undergoing intraperitoneal dialysis and continuous ambulatory peritoneal dialysis. In such patients, a loading dose of 1 gram of Tazicef may be given, followed by 500 mg every 24 hours. In addition to IV use, Tazicef can be incorporated in the dialysis fluid at a concentration of 250 mg for 2 L of dialysis fluid.

Note: Generally Tazicef should be continued for 2 days after the signs and symptoms of infection have disappeared, but in complicated infections longer therapy may be required.

Administration

Tazicef may be given intravenously or by deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh. Intra-arterial administration should be avoided (see PRECAUTIONS).

Intramuscular Administration

For IM administration, Tazicef should be reconstituted with one of the following diluents: Sterile Water for Injection, Bacteriostatic Water for Injection, or 0.5% or 1% Lidocaine Hydrochloride Injection. Refer to Table 7.

Intravenous Administration

The IV route is preferable for patients with bacterial septicemia, bacterial meningitis, peritonitis, or other severe or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present or pending.

For direct intermittent IV administration, reconstitute Tazicef as directed in Table 7 with Sterile Water for Injection. Slowly inject directly into the vein over a period of 3 to 5 minutes or give through the tubing of an administration set while the patient is also receiving one of the compatible IV fluids (see COMPATIBILITY AND STABILITY).

For IV infusion, reconstitute the 1-gram or 2-gram vial and add an appropriate quantity of the resulting solution to an IV container with one of the compatible IV fluids listed under the COMPATIBILITY AND STABILITY section.

Intermittent intravenous infusion with a Y-type administration set can be accomplished with compatible solutions. However, during infusion of a solution containing ceftazidime, it is desirable to discontinue the other solution.

Table 7. Preparation of Solutions of Tazicef


Vial

Size

Amount of

Diluent to

Be Added


Approximate

Available Volume

Approximate

Ceftazidime

Concentration

Intramuscular

1 gram

3.0 mL

3.6 mL

280 mg/mL

Intravenous Infusion

1 gram

10 mL

10.6 mL

95 mg/mL

2 gram

10 mL

11.2 mL

180 mg/mL

All vials of Tazicef as supplied are under reduced pressure. When Tazicef is dissolved, carbon dioxide is released and a positive pressure develops.

Solutions of Tazicef, like those of most beta-lactam antibiotics, should not be added to solutions of aminoglycoside antibiotics because of potential interaction.

However, if concurrent therapy with Tazicef and an aminoglycoside is indicated, each of these antibiotics can be administered separately to the same patient.

Hide
(web2)